Business Wire

Chugai's Bispecific Antibody Emicizumab to Present Results of Two Pivotal Phase lll Studies at ISTH

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced results from two global phase lll studies for Chugai’s bispecific antibody emicizumab (ACE910): the primary analysis of HAVEN 1 study (NCT02622321) and the interim analysis of HAVEN 2 study (NCT02795767). The data will be presented on July 10 at the upcoming 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin, Germany (July 8 to 13). Both studies were conducted in haemophilia A with inhibitors, while HAVEN 1 is for adult and adolescent patients and HAVEN 2 is for paediatric patients.

HAVEN 1 Study

Study description

HAVEN 1 is a randomised, multicentre, open-label, global phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab once-weekly subcutaneous injection for 24 weeks or longer in adults and adolescents (12 years of age or older) with haemophilia A with inhibitors to factor VIII.

Study design     n=109

  • Patients previously treated with on-demand bypassing agents (BPAs) were randomised in a 2:1 fashion to Arm A or B
        Arm A (n=35):       emicizumab once-weekly dosing
Arm B (n=18): no prophylaxis (on-demand BPA)
  • Patients previously treated with prophylactic BPA
        Arm C (n=49):       emicizumab once-weekly dosing
  • Patients who participated in a forgoing Non-Interventional Study (NIS) and previously on BPA (on-demand or prophylactic)
        Arm D:       emicizumab once-weekly dosing

On-demand use of BPAs was allowed to treat breakthrough bleeds per protocol in all arms.

Summary of results

  • The primary endpoint was achieved with a statistically significant reduction in bleed rate of 87% (risk rate [RR]=0.13, p<0.0001) in treated bleeds with emicizumab (Arm A) compared with on-demand treatment with BPAs (Arm B). All secondary endpoints were also achieved with consistent reductions in bleed rates.
       

[Major secondary endpoints and reduction rate (%) compared with on-demand BPAs]

All bleeds:       (80%, RR=0.20, p<0.0001)
Treated spontaneous bleeds: (92%, RR=0.08, p≤0.0001)
Treated joint bleeds: (89%, RR=0.11, p=0.0050)
Treated target joint bleeds: (95%, RR=0.05, p=0.0002)
  • After a median observation time of 31 weeks, 62.9% of patients receiving emicizumab experienced zero treated bleeds (Arm A) compared to 5.6% of those receiving on-demand BPAs (Arm B).
  • Results also showed a statistically significant improvement in health-related quality of life (HRQoL) measured at 25 weeks with emicizumab (Arm A) compared to on-demand BPAs (Arm B).
  • Among patients who had previously received prophylactic use of BPAs and then received emicizumab (Arm C), 24 patients had participated in the foregoing NIS, which was conducted without emicizumab. An intra-patient analysis in this group showed a 79% (RR=0.21, p=0.0003) reduction in treated bleeds receiving emicizumab compared to their prior prophylaxis with BPAs.
  • Adverse events (AEs) occurring in 5% or more of patients treated with emicizumab were injection site reactions, headache, fatigue, upper respiratory tract infection and arthralgia.
  • Serious adverse events were reported with thromboembolic events (TE) in two patients and thrombotic microangiopathy (TMA) in three patients (one patient experienced TMA after the clinical data cut off for primary analysis) while receiving emicizumab prophylaxis. The TE and TMA events were associated with repeated high doses of a BPA, activated prothrombin complex concentrate, when used to treat breakthrough bleeds.

HAVEN 2 Study

Study Description

HAVEN 2 is a single-arm, multicentre, open-label, global phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab once weekly subcutaneous injection in paediatric patients with haemophilia A with inhibitors to factor VIII.

Interim analysis

The interim analysis was conducted with 19 children younger than 12 years of age with haemophilia A with inhibitors who require treatment with BPAs. The median observation time was 12 weeks.

Summary of results

  • Only one of 19 children receiving emicizumab reported a treated bleed. There were no reported joint or muscle bleeds.
  • An intra-patient comparison (n=8) in patients who were previously enrolled in the NIS showed that all patients experienced zero treated bleeds or a 100% reduction after emicizumab treatment (previous annualized bleeding rate ranged from 0 to 34.24); this included seven children who had received prior BPA prophylaxis, and one who had received prior on-demand BPA.
  • Data indicated that the same dose of emicizumab is appropriate for children as for adults and adolescents, based on the levels of emicizumab in the blood (pharmacokinetics) of the children compared with the level of emicizumab in the blood of adults and adolescents.
  • The most common AEs with emicizumab in the HAVEN 2 study were mild injection site reactions and common cold symptoms (nasopharyngitis).
 

Summary of the HAVEN 1 (NCT02622321) study results to be presented at ISTH

Study Description   Phase III randomised, multicenter, open-label study evaluating the efficacy, safety, and pharmacokinetics of emicizumab prophylaxis versus no prophylaxis in people with hemophilia A with inhibitors to factor VIII.
Patients

Patients with hemophilia A with inhibitors aged ≥12 years on episodic or prophylactic treatment with bypassing agent(s)
N=109

Study group  

No prophylaxis
(prior episodic BPAs)
(Arm B; n=18)

 

Emicizumab prophylaxis
(prior episodic BPAs)
(Arm A; n=35)

Treated bleeds ABR (primary endpoint)
Annualized bleeding rate [ABR]*

(95% CI)

23.3
(12.33; 43.89)

2.9
(1.69; 5.02)

% reduction (RR, p-value)

87% reduction
(RR= 0.13, p<0.0001)

Median ABR

(Interquartile range; IQR)

18.8
(12.97; 35.08)

0.0
(0.00; 3.73)

% patients with zero bleeds (95% CI)  

5.6
(0.1; 27.3)

 

62.9
(44.9; 78.5)

 

Treated bleeds ABR intra-patient comparison

(Arm C patients who participated in NIS n=24; secondary endpoint)

Study group   Prior prophylaxis with BPAs   Emicizumab prophylaxis
ABR*

(95% CI)

15.7
(11.08; 22.29)

3.3
(1.33; 8.08)

% reduction (RR, p-value)

79% reduction
(RR= 0.21, p=0.0003)

Median ABR (IQR)

12.0 [5.73; 24.22]

0.0 [0.00; 2.23]
% patients with zero bleeds  

12.5
(2.7; 32.4)

 

70.8
(48.9; 87.4)

*Negative binomial regression model

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.

In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totalled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The 6th Annual World Patient Safety, Science & Technology Summit Kicked off with an Important Announcement about the Progress Being Made to Save Lives in Hospital Settings24.2.2018 10:00Pressemelding

The 6th Annual World Patient Safety, Science & Technology Summit kicked off with an important announcement about the progress being made to save lives in hospital settings. Nearly 4,600 hospitals in 44 countries have committed to adopting patient safety processes that are proven to eliminate preventable deaths in hospitals. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180224005027/en/ England’s Health and Social Care Secretary, Rt. Hon. Jeremy Hunt, launches groundbreaking new measures on Day One of the 6th Annual World Patient Safety, Science & Technology held in London (Photo: Business Wire) The Patient Safety Movement Foundation has taken on an inspiring and ambitious goal of reducing preventable patient deaths in hospitals to ZERO by 2020. The annual Summit in central London plays a major role in taking on that challenge with the participation of 300 global leaders, medical experts, medical technology CEOs, and patient

WuQi Technologies is Latest Licensee of CCww’s NB-IoT UE Protocol-Stack Software24.2.2018 09:06Pressemelding

Communications Consultants Worldwide Ltd. (CCww), global innovator of 3GPP® technologies, has licensed its NB-IoT protocol-stack software to WuQi Technologies Inc., a leading global developer of highly integrated mixed-signal SoC solutions, and the latest licensee of CCww’s NB-IoT Release 13 UE protocol-stack software. Communications Consultants Worldwide (CCww) is working with WuQi Technologies for the integration of its NB-IoT protocol-stack software onto WuQi Technologies’ highly innovative SoC. This relationship, catalyzed by T2M, is enabling the production of a highly integrated, very low power, NB-IoT SoC chipset targeting IoT Smart City, Smart Home, and wearable applications. CCww’s CEO, Richard Carter, said, “NB-IoT is CCww’s latest cellular Protocol-stack SW. We are excited to be working with WuQi to enable a sector-leading NB-IoT SoC, pushing back boundaries of performance and battery life for the next generation of IoT. See our demonstration at the Mobile World Congress (Hal

IDEMIA and Octo Telematics Reinvent Car Sharing Experience by Adding Facial Recognition to EasyOpen Solution23.2.2018 15:57Pressemelding

IDEMIA, the global leader in Augmented Identity for an increasingly digital world, announces today that it has implemented facial recognition technology on EasyOpen, a solution previously developed with its partner Omoove, a wholly-owned Octo Telematics company, Europe’s leading Shared Mobility technology provider. The digital enrolment process combined with facial recognition technology will securely enroll and authenticate the driver before EasyOpen automatically opens the car. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180223005506/en/ (Photo: Idemia) You will never rent a car the same way thanks to EasyOpen solution that combines IDEMIA’s expertise in secure service enablement and Omoove’s experience in Shared Mobility platforms and on-board technology. The first version of the solution was launched last year and allows drivers, who have already registered on the application, to use their smartphones as a key to open

SM-Optics Unveils First FLEXSET Chip, Paving the Way to Optical Micro Nodes23.2.2018 14:00Pressemelding

SM-Optics launches FLEXSET, a single chip embedding multiple processing functionalities raising the bar for performances, density and architectural flexibility. The FLEXSET is the heart of the Lightmode product family. FLEXSET OTN switching matrix scales from 300Gbps to 1Tbps and can be addressed by ports spanning from traditional low-speed services like 2Mbps over micro-OTN, to layer2 and layer3 over ODUFlex, 100G over ODU4 and 200G over FlexO. Thanks to its embedded capabilities including multi-technology OAM, packet processing, synchronization and fast protection functions, FLEXSET operates by design at the lowest latency performances and features an Intel Stratix 10 FPGA. Following the launch of micro-OTN, a revolutionary approach to efficiently extend OTN protocol to low speed services, the launch of FLEXSET advances the vision of a highly interconnected metro network and of micro nodes. Revolving around functional block elements, micro nodes collapse in few rack units OTN and pho

Bitcoin Miner HashGains’ Crowdsale to Build Green Cloud Mining Data Centers Receives Excellent Response23.2.2018 13:56Pressemelding

HashGains.com, a leading cryptocurrency mining platform, has launched its crowdsale program to build mega cryptocurrency cloud mining data centers in India and Canada which uses renewable energy like wind and solar as source of energy. “With the growing worries around bitcoin mining causing environmental damage, difficulty levels of mining increasing and returns heading southwards, there was no better opportunity but to build green energy data centers which run on free sources of energy like wind and solar, ensuring handsome mining rewards while taking care of environment,” said Mr Anuj Bairathi, CEO & Founder, HashGains, who is crypto enthusiast himself. HashGains is a growing cloud mining platform with more than 10,000 active customers enjoying mining returns and is expected to reach the mark of 1 million customers by 2020. To handle such a massive growth and ever growing demand of customers, it becomes even more important that mega mining centers are planned which can serve needs of

Stratecast Recognizes CARDINALITY as a “10 to Watch in 2018”23.2.2018 13:07Pressemelding

In their new report, “Digital Transformation Means New Tools for New Business” —part of the Global Operations, Orchestration, Data Analytics, and Monetisation (ODAM) stream—Stratecast recognises CARDINALITY for their new approach towards processing big data to deliver applications such as Customer Experience, Operational Intelligence, Network Analytics, Churn Management and Marketing Intelligence. Stratecast identified that the CARDINALITY Perception Platform brings large amounts of data from multiple CSP sources together in order to address a growing group of data analysis needs from different operational work teams and the wider business. It also does this at ingestion rates and storage levels previously thought not practical. "Using design principals tied to microservices and containerized solution components, the platform is a major advancement in meeting CSP data analysis needs at a price untouchable by previously-defined platforms," said Karl Whitelock, Stratecast director of glo